Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Capivasertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 known ✓ | P31749 | 20/20 | 1.00 |
| ▸ | AKT2 known ✓ | P31751 | 8/20 | 1.00 |
| ▸ | AKT3 known ✓ | Q9Y243 | 8/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 8/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 2/20 | 1.00 |
| ▸ | LATS1 | O95835 | 2/20 | 1.00 |
| ▸ | PRKCB | P05771 | 2/20 | 1.00 |
| ▸ | RET | P07949 | 2/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 2/20 | 1.00 |
| ▸ | PRKCA | P17252 | 2/20 | 1.00 |
| ▸ | PRKACA | P17612 | 2/20 | 1.00 |
| ▸ | PRKACB | P22694 | 2/20 | 1.00 |
| ▸ | GRK2 | P25098 | 2/20 | 1.00 |
| ▸ | CLK1 | P49759 | 2/20 | 1.00 |
| ▸ | LIMK1 | P53667 | 2/20 | 1.00 |
| ▸ | LIMK2 | P53671 | 2/20 | 1.00 |
| ▸ | PRKAG1 | P54619 | 2/20 | 1.00 |
| ▸ | PRKCQ | Q04759 | 2/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 2/20 | 1.00 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Capivasertib SCHEMBL390243 | 1.00 | AKT1 (1.00) | AKT1ROCK2AKT2AKT3PRKD3 | |
| Capivasertib SCHEMBL29557103 | 1.00 | AKT1 (1.00) | AKT1ROCK2AKT2AKT3PRKD3 | |
| Capivasertib SCHEMBL390244 | 1.00 | AKT1 (1.00) | AKT1ROCK2AKT2AKT3PRKD3 | |
| Capivasertib SCHEMBL391382 | 1.00 | AKT1 (1.00) | AKT1ROCK2AKT2AKT3PRKD3 | |
| SCHEMBL386620 | 0.95 | AKT1 (1.00) | AKT1ROCK2AKT2AKT3PRKD3 | |
| SCHEMBL386619 | 0.95 | AKT1 (1.00) | AKT1ROCK2AKT2AKT3PRKD3 | |
| SCHEMBL390401 | 0.95 | AKT1 (1.00) | AKT1ROCK2AKT2AKT3PRKD3 | |
| SCHEMBL391567 | 0.93 | AKT1 (1.00) | AKT1ROCK2AKT2AKT3PRKD3 | |
| SCHEMBL393210 | 0.93 | AKT1 (1.00) | AKT1ROCK2AKT2AKT3PRKD3 | |
| SCHEMBL21619156 | 0.93 | AKT1 (1.00) | AKT1ROCK2AKT2AKT3PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12252495-B2 | Protein kinase B inhibitors | ASTRAZENECA AB (SE) | 2025-03-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12252495-B2 | Protein kinase B inhibitors | PRKAR2B, PRKCB, AKT1 | AKT1 3/4885AKT2 4/4885AKT3 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.